Healthcare Industry News: U.S. Food and Drug Administration
News Release - November 7, 2017
Welch Allyn Introduces Connex(R) Cardio ECGCombines Leading Algorithm, Wireless Technology and Flexible EMR Connectivity to Help Improve Clinician Decision-Making and Enhance Patient Outcomes
CHICAGO, Nov. 7, 2017 -- (Healthcare Sales & Marketing Network) -- Hill Rom's (NYSE: HRC) Welch Allyn business today introduced the Connex® Cardio ECG, a PC-based resting electrocardiograph (ECG) designed to help improve clinician decision-making and simplify clinical workflows.
When it comes to patients' heart health, an ECG may be the most important test a physician runs. The Welch Allyn Connex Cardio ECG helps physicians identify, manage and track conditions like heart disease and stroke by combining the clinical excellence of Mortara technology with Welch Allyn EMR connectivity expertise. The result is a solution that delivers accurate, high-fidelity ECG tests to a physician in as few as two clicks.
The Connex Cardio ECG uses the widely recognized VERITAS™ interpretation algorithm, which complies with American College of Cardiology (ACC), American Heart Association (AHA) and Heart Rhythm Society (HRS) recommendations for ECG filtering and acquisition on adult and pediatric patients. Physicians can have confidence in the data they are reviewing because good measurements from uncompromised signal acquisition are the foundation for solid automatic interpretation algorithms. The VERITAS algorithm is used by the U.S. Food and Drug Administration to monitor patients participating in phase 1 and phase 2 drug trials, as well as when new drug applications are submitted to the FDA's ECG Warehouse for cardiac safety review.
"Better patient outcomes begin with better data, which is why we incorporated the VERITAS resting ECG algorithm in the Connex Cardio solution," said Alton Shader, president of Hill-Rom's Front Line Care business, which includes Welch Allyn. "Health care providers can be confident they are interpreting the right data to support the best clinical decisions."
Connex Cardio is designed to support each practice's clinical workflow—from exam to documentation. Clinicians can launch from the EMR to capture and save an ECG in as few as two clicks with connectivity with leading EMR partners. Furthermore, the unique WAM™ wireless acquisition module enables easy, efficient ECG capture with no cable tether between the patient and the PC.
Connex Cardio represents the first new product introduction since Mortara products became part of the Welch Allyn cardiopulmonary line. With a broad range of diagnostic cardiology solutions, the combined solution set helps people get better care, inside and outside the hospital. Backed by clinical excellence, connected solutions and continuous innovation, Welch Allyn Cardiology is proud to be powered by Mortara.
Currently available in the U.S., Connex Cardio is planned for global distribution in 2018.
About Hill-Rom Holdings, Inc.
Hill-Rom is a leading global medical technology company with more than 10,000 employees worldwide. We partner with health care providers in more than 100 countries, across all care settings, by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: Advancing Mobility, Wound Care and Prevention, Patient Monitoring and Diagnostics, Surgical Safety and Efficiency and Respiratory Health. Hill-Rom's people, products and programs work towards one mission: Every day, around the world, we enhance outcomes for patients and their caregivers. Visit www.hill-rom.com for more information.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.